Reported 2025 revenue of $9.027 million, a 6% increase from $8.538 million in 2024. Experienced a net loss of $2.470 million, or $0.90 per diluted share, for 2025, compared to a net loss of $1.053 million, or $0.41 per diluted share, in 2024. The increased net loss was primarily due to a one-time, non-cash charge of $1.738 million for an increased valuation allowance for deferred taxes in 2025, up from $187 thousand in 2024. Excluding this deferred tax valuation allowance, the loss before taxes declined by $94 thousand to $1.311 million in 2025 from $1.405 million in 2024. Gross margin remained stable at 40.3% in 2025, compared to 40.4% in 2024. Made significant progress on the SpinDetect Centrifugal Drug Analyzer, with focus on production mold fabrication in Q1 2026 and first article moldings expected in April 2026.